Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three Studies Support Medtronic’s Cryoablation Systems As ‘First Line’ AFib Treatment

Executive Summary

Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.

You may also be interested in...



FDA Approves Medtronic’s Arctic Front For ‘First-Line’ Treatment For AFib

The new approval allows Medtronic to promote cryoablation as the first option for patients with recurrent symptomatic paroxysmal atrial fibrillation. Previously, it was only approved for patients who had already tried to manage their atrial fibrillation with drugs.

Medtronic, Farapulse Advance Pulsed Field Ablation With US Trials

Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.

Medtronic Claims Share Gains In Cardiovascular And Neurostim

The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT143109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel